Handelsbanken Fonder Ab Revance Therapeutics, Inc. Transaction History

Handelsbanken Fonder Ab

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	BUY	$5.81 - $11.2 $42,413 - $81,760	7,300 Added 54.07%	20,800 $183,000
Q2 2023 Aug 02, 2023	BUY	$24.7 - $37.61 $54,340 - $82,742	2,200 Added 19.47%	13,500 $342,000
Q4 2022 Feb 07, 2023	BUY	$18.32 - $30.66 $32,976 - $55,188	1,800 Added 18.95%	11,300 $209,000
Q3 2022 Oct 27, 2022	BUY	$14.33 - $28.47 $136,135 - $270,465	9,500 New	9,500 $256,000
Q1 2022 May 11, 2022	SELL	$12.36 - $20.31 $198,996 - $326,991	-16,100 Closed	0 $0
Q2 2021 Aug 03, 2021	BUY	$26.8 - $31.84 $431,480 - $512,624	16,100 New	16,100 $477,000

232

82.1M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.